PHN / Healthcare Number	Accession #	Molecular Diagnostic Laboratory Requisition			ic	LABORATORY MEDICINE AND PATHOLOGY Client Response Centre (780) 407-7484 CAPITAL HEALTH REGION LABORATORIES DynaLIFE DX		
□ M Patient Legal Name (Last)	(First)	(Initial) D DD MM			YY	□ Copy to		
of .		, , , O B				Name		
Address		City Prov. Postal Cod				Physician Code		
Chart #	Patient Ph	atient Phone # Lab #				Address		
Gliait #	rauentri	one # Lab #				Bill Type CPL □ Alberta Health Care	□ PRIORITY	
Ordering Physician / Practitioner		Physician Code		en Event		OR	(specify tests)	
		Report Location Code  Report Location Code				CO  Company OT  Out of Prov XX  Pre-paid PB  Patient Bill		
Ordering Address / Location						Co. name		
Depart address if different						Address		
Report address if different		EN □ ENVIRON WCB □ WORKER			Client #	Phone to		
Date specimen collected Col. Location		COMP			Cilent#			
DD MM YY 1. INDICATION <b>MUST BE</b> PROVIDED BEFORE ANY GENET TESTING CAN BE DONE.					;			
2. DECLI TO WILL ONLY BE PROVIDED IS ALL THE								
TIME (24 h) Collector		ECTIONS OF THE REQUIS Y FILLED OUT.	SITION ARE					
	OOMI LETEL	T TILLED OUT.						
SPECIMENS	PED	PEDIGREE:			TE	EST REQUESTED		
□ Blood					ALS	S Amyotrophic Lateral Sclerosis		
☐ 15 mL EDTA (mauve top)		A pedigree minimally indicating (with				RX		
☐ 3 mL EDTA up to 1 year of a	age	names) parents, sibs and children MUST			ANG			
(then 3 mL / kg to a max. o	,, 10 IIIL)	accompany this requisition.			CF	DVS Del 22q11.21 - 23 (Di George and Velocardiofacial Syndromes)		
CVS: 10 mg minimum -					DVS			
Amniotic: Fluid 25 mL min.					ED2			
Other (specify)					FRA	RAX  Fragile X		
Date Specimen Drawn					НС	C Hemochromatosis		
Recent Transfusion (date if known)						HOKPP  Hypokalemic Periodic Paralysis		
Ethnic background						HUNT Huntington Disease		
Your reference No.						LCAD Long Chain Acyl-CoA Dehydrog Def MCAD Med Chain Acyl-CoA Dehydrog Def		
UAHMDL reference No						MCAD  Med Chain Acyl-CoA Dehydrog Def MTHFR  Methylene Tetrahydrofolate Reductase Deficiency		
Family Doctor					IVIII			
					MYI	MYD Myotonic Dystrophy		
INDICATION: (Check all relevant	hoxes)					NHL		
☐ Prenatal Testing (specify LMP	•				OPI	OPMD Oculopharangeal Muscular		
yy / mm / dd					DDG	Dystrophy PRSS ☐ Hereditary Pancreatitis		
☐ Confirmation of clinical diagno					PW			
☐ Presymptomatic testing					SPN			
☐ Carrier status					TOF	<del></del>		
☐ Bank sample until further notic	е				WM			
☐ Other					UPI		arental	
Clinical Features / Comments		I have reviewed the points on the back				samples required) (specify chromosome)_		
		s form, as well as the			HC/			
		limitations of genetic testing with the patient / guardian. I have answered all the patient's / guardian's questions and have obtained verbal concept to order.				restricted to Edmonton and Calgary genetics clinics) (specify)		
					MD			
FAMILY HISTORY: (Required)	the a	the above test(s).			יטוטי	MDG ☐ Other (specify name and MIM#)		
Other family members tested prev	iously? Phys	Physician / Genetic Counsellor						
Yes No		print name			MD	IDL USE ONLY		
INDEX Patient Name						Patient No.		
		signature				Family No.		
		SEE BACK OF FORM				Possived		



## **Pre-test Counselling Information**Molecular Genetic Diagnostic Testing



We recommend that the following points be discussed with the patient and / or guardian(s) prior to ordering molecular testing through the Molecular Diagnostic Laboratory at the Stollery Children's Hospital.

- 1. Blood or tissue samples (ex. amniotic fluid, chorionic villi) will be collected and DNA will be extracted. After the test(s) is completed, any remaining DNA will be banked in the laboratory.
- 2. Current testing may not be able to detect all genetic mutations associated with the suspected condition. The accuracy, implications and limitations of this testing should be reviewed prior to testing.
- 3. DNA analysis is limited to the requested test and cannot rule out all other genetic conditions or mutations. The correct clinical diagnosis is important for accurate DNA results.
- 4. Improved or additional testing may become available either because of changes in laboratory techniques or because of new information regarding the genetic cause of the condition(s). In some cases, when improved or additional testing becomes available at the Molecular Diagnostic Laboratory at the Stollery Children's Hospital, the patient's DNA may be re-tested. When possible, the patient and / or ordering physician will be contacted if a mutation or clinically significant gene change is identified.
- 5. Confidentiality will be maintained to the best of our ability as required by the applicable health privacy laws and the College of Physicians and Surgeons of Alberta. The results may be used anonymously to help interpret test results for other family members. Information that DNA has been banked may be shared to prevent needless repeat blood drawing.
- 6. DNA testing may reveal information about genes or gene changes other than the requested genetic test. The significance of such a gene change may be unclear. DNA testing may also uncover non-paternity or an undisclosed adoption. Accurate test results depend on knowing the correct relationship between family members.
- DNA may be given to research centres, with appropriate research ethics board approval, to help further research. Identifying patient information will be kept confidential.
- 8. Participation in genetic testing is completely voluntary. The patient may withdraw consent or request that their DNA sample be discarded at any time.
- 9. DNA testing may result in some forms of discrimination (insurance, employment or other).
- 10. Testing is based on the current level of knowledge in medical genetics. It is the patient and / or physician's responsibility to periodically seek up-dated information especially before any reproductive decisions are made. The patient is responsible for keeping their physician(s) informed of address changes and new medical and family history information.